Generic depression patch tested against brand in small study
NCT ID NCT06607744
First seen Feb 27, 2026 · Last updated May 17, 2026 · Updated 10 times
Summary
This study tested a generic version of the selegiline skin patch (6 mg/24 hours) against the brand-name EMSAM in 12 healthy adults. The goal was to see if the generic patch delivers the same amount of medicine into the body and to check for skin irritation. This was a pilot study, meaning it helps plan larger studies, and does not directly treat depression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Ampang
Ampang, Selangor, 68000, Malaysia
-
Sarawak General Hospital
Samoran, Sarawak, 94300, Malaysia
Conditions
Explore the condition pages connected to this study.